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a b s t r a c t
Mucosal surfaces of the gastrointestinal tract play an important role in immune homeostasis and defense
and may be compromised by enteric disorders or infection. Therapeutic intervention using monoclonal
antibody (mAb) offers the potential for treatment with minimal off-target effects as well as the possibility
of limited systemic exposure when administered orally. Critically, to achieve efficacy at luminal surfaces,
mAb must remain stable and functionally active in the gastrointestinal environment. To better under-
stand the impact of isotype, class, and molecular structure on the intestinal stability of recombinant anti-
bodies, we used an in vitro simulated intestinal fluid (SIF) assay to evaluate a panel of antibody candidates
for enteric mAb-based therapeutics. Recombinant IgG1 was the least stable following SIF incubation,
while the stability of IgA generally increased upon polymerization, with subtle differences between sub-
classes. Notably, patterns of variability within and between mAbs suggest that variable regions con-
tribute to mAb stability and potentially mediate mAb susceptibility to proteases. Despite relatively
rapid degradation in SIF, mAbs targeting Enterotoxigenic Escherichia coli (ETEC) displayed functional
activity following SIF treatment, with SIgA1 showing improved function compared to SIgA2. The results
of this study have implications for the design of enteric therapeutics and subsequent selection of lead
candidates based upon in vitro intestinal stability assessments.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Immune responses at the mucosal surface of the gastrointesti-
nal (GI) tract play a crucial role in defense against pathogens as
well as regulating inflammatory responses against commensal
gut microbes and food antigens. The consequences of enteric infec-
tion or of immune dysregulation can be significant; immune disor-
ders such as inflammatory bowel disease (IBD) affect over 0.3% of
the population in parts of the developed world [1], and it is esti-
mated that bacterial diarrheal diseases alone result in 1.3 million
deaths per year [2]. Despite considerable effort, significant chal-
lenges remain in the treatment of GI infections. Vaccines against
many pathogens have yet to be developed, and in any event may
not be sufficient to protect some high-risk groups such as very
young, elderly, or immunocompromised individuals. Thus, the
development of new therapeutics and delivery modalities capable
of preventing infection or inflammation at the mucosal surface
remains an important goal.
Over the last several decades the number of licensed mono-
clonal antibody (mAb)-based therapeutics has increased substan-
tially, with 79 mAbs approved by the US Food and Drug
Administration as of December 2019, including several targeting
IBD [3]. While such successes support the further development of
enteric mAb-based therapeutics, the gastrointestinal environment
presents significant challenges for mAb delivery and potency.
MAb is susceptible to pH-dependent and protease-mediated cleav-
age in the GI tract as well as degradation by bacterial products in
the colon, leading to loss of function [4–6]. Further, following
delivery to luminal surfaces functional mAb must persist for suffi-
cient time to achieve efficacy. Thus, primary design considerations
for enteric mAb therapeutics must include formulation and opti-
mization for protease resistance, retention in the GI tract, and suf-
ficient functional half-life to achieve efficacy. Studies using IgG
have shown limited success in this regard [5–8], and other anti-
body classes have been investigated with the goal of enhanced sta-
bility at luminal surfaces [9,10].
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Both immunoglobulin G (IgG) and secretory IgA (sIgA) are abun-
dant in mucosal secretions and surfaces. SIgA consists of IgA mono-
mers joined covalently by J-chain and associated with the
extracellular domains of the polymeric Ig receptor, termed secre-
tory component (SC) [11]. IgA is expressed as two subclasses,
IgA1 and IgA2, which differ in the length of the hinge region, gly-
cosylation pattern, and positioning of several intermolecular disul-
fide bonds as well as structural morphology [11,12]. In the
intestine, sIgA functions to prevent infection and illness through
immune exclusion of pathogens and toxins and performs other
critical immune functions [13]. Additionally, sIgA is able to associ-
ate with mucosal surfaces [11,13–15], and is more resistant to pro-
teolysis than is IgG [11,16]. The presence of SC also serves to mask
several protease cleavage sites in Ca domains, leading to greater
protease resistance compared to monomeric and dimeric IgA (the
latter possessing J chain but lacking SC) [11,12]. Further, a number
of passive immunization studies support the efficacy of sIgA to pro-
tect against pathogens [17–21]. Thus, recombinant (S)IgA is a
promising candidate for enteric therapeutics applications, and sev-
eral SIgA-based constructs are currently being developed by
groups utilizing CHO-cell and plant-based expression systems
[22,23].
Streamlining development of mAb-based therapeutics targeting
the GI tract will require the inclusion of structural and functional
stability assays as criteria for lead selection early in the discovery
pipeline. In particular, such assays should be small-scale, require
minimal material, be compatible with a number of downstream
analytical methods, and permit high enough throughput to enable
down selection prior to more costly and time-consuming in vivo
studies. A number of recent studies have been undertaken to estab-
lish consensus in vitro digestion models using simulated gastric
and intestinal fluid (SGF and SIF respectively) to accurately mimic
in vivo digestion conditions [24–26]. While generally employed at
larger scales for nutrition studies, these models have potential
applications for early stage stability studies of enteric therapeutics.
Here we have used a simulated intestinal stability assay to evalu-
ate a panel of mAbs representing different isotypes, subclasses,
and molecular structures directed against toxoid, bacterial, and
viral antigens. Our results showed that mAbs expressed as IgA dis-
played better stability profiles than did IgG, with the greatest sta-
bility being observed for SIgA. Overall, this model has potential as a
new tool for the early stage discovery of mAb-based therapeutics
targeting the intestine and has implications for the development
of oral delivery strategies.
2. Materials and methods
2.1. Antibodies and reagents
A total of four mAbs were used for these studies. MAb1 was iso-
lated as an IgA1 from the peripheral blood mononuclear cells
(PBMC) of a patient challenged with ETEC and is reactive against
the heat labile enterotoxin B subunit. A recent study has exten-
sively characterized the structure, glycosylation profile, and stabil-
ity of this mAb [22]. MAb2 was isolated as an IgG1 using PBMCs
from an HIV + patient and is reactive with gp120 [27]. The variable
regions of both antibodies were subsequently sequenced and
cloned in frame with human IgG1, IgA1 or IgA2(m1) constant
regions using a proprietary DNA vector. Two antibodies from the
panel described in [28] (mAb3 and mAb4 - both IgG1) were origi-
nally isolated from transgenic mice expressing human
immunoglobulin genes (HuMab) immunized with the ETEC colo-
nization factor antigen adhesin subunit CfaE, and variable regions
were cloned to generate isotype-specific mAb as above. All anti-
bodies used the kappa light chain, and all antibodies of a given iso-
type contained identical plasmid-encoded heavy and light constant
regions. Recombinant dimeric IgA (dIgA) was produced using
either stable cell lines (mAb1 and mAb2) or transiently transfected
CHO cells (mAb3 and mAb4) with the ExpiCHO expression system
(Life Technologies) expressing the heavy and light chain as well as
J-chain. SIgA was produced by co-culturing dIgA-expressing cells
with cells expressing secretory component. MAb was purified from
supernatant over either a CaptureSelect (ThermoFisher) or Capto L
(GE Healthcare) affinity column followed by size exclusion chro-
matography (SEC) using a HiLoad 26/600 Superdex column on a
GE AKTA Pure chromatography system. Following SEC, mAb was
dialyzed and concentrated in phosphate buffered saline (PBS) pH
7.2. Concentration was determined either by analytical SEC or by
ELISA by comparison with a known standard and mAbs were
stored at 4 C prior to use.
Heat labile enterotoxin B subunit of E. coli was purchased from
Sigma-Aldrich (#E8656). Recombinant gp120 and the N-terminal
adhesion domains of CfaE have been described previously [28,29]
and were produced at MassBiologics for this study. ETEC strain
H10407 expressing CFA/I fimbriae was obtained from the Ameri-
can Type Culture Collection (ATCC 35401).
2.2. SIF stability assay
Purified mAb was evaluated for intestinal stability using a mod-
ified assay (Fig. S1) based on a consensus adult digestion model
designed to simulate gastrointestinal conditions in vitro [26]. SIF
mimicking fasting conditions was prepared using FaSSIF/FeSSIF/
FaSSGF powder (Product code FFF01) from Biorelevant according
to the manufacturer’s instructions. The fasting state was specifi-
cally selected to minimize confounding variables such as the pres-
ence of exogenous food protein associated with the fed state.
Briefly, to prepare the dissolution buffer, 0.344 g of sodium phos-
phate anhydrous (NaH2PO4) and 0.619 g of NaCl was dissolved in
100mLs H2O and pH adjusted to 7.0. To prepare SIF, FaSSIF/FeS-
SIF/FaSSGF powder (0.224 g) was dissolved in 50 mL dissolution
buffer to permit optimal micelle formation, after which an addi-
tional 50 mL of buffer was added and allowed to stand for at least
two hours in the dark prior to use. All SIF was used within 48 h of
preparation. Thirty minutes prior to the start of the assay, porcine
pancreatin (10 mg/mL, Sigma-Aldrich P1625) was added and SIF
was prewarmed to 37 C.
Prior to incubation with SIF, all antibodies were diluted to a
final concentration of 500 nM in deionized H2O. Seven hundred
microliters of SIF + pancreatin was added to 16x100mm disposable
glass culture tubes containing a small magnetic stir bar on a stir
plate set to low spin at 37 C. To begin the assay, 300 lL of each
antibody in H2O was added to each culture tube for a final mAb
concentration of 150 nM. Samples (200 lL) were taken at T = 5,
=30, =60, and =120 min time points and immediately placed on
ice in 1.5 mL microcentrifuge tubes. Halt Protease Inhibitor Cock-
tail (Thermo Scientific #87786) and EDTA was added to a final con-
centration of 1X and 5 mM, respectively. Samples were centrifuged
for ten minutes at 16,000g at 4 C to pellet particulates and super-
natant transferred on ice to new tubes. Aliquots were used imme-
diately for ELISA and PAGE analysis, and remaining sample was
stored at 80 C for functional assays. Each SIF assay and subse-
quent analysis was performed independently at least three times
(with the exception of mAb3 dIgA2, where due to limited reagent
N = 2).
2.3. Enzyme-linked immunosorbent assay (ELISA)
SIF treated samples were evaluated for immunoreactivity using
antigen-specific ELISA. For IgG and mIgA ELISA, Corning polystyr-
ene 96-well plates (#9018) were coated overnight at 4 C with
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antigen (LT, gp120, or CfaE) at 100 ng/well followed by blocking
with ELISA buffer (1X Blocker BSA [ThermoFisher #37525], 0.05%
Tween-20 in PBS). SIF samples were diluted in ELISA buffer to a
final concentration of 1 lg/mL based upon the initial concentration
of antibody used in the assay and titrated 2-fold. Following a thirty
minute incubation, plates were washed 3x with PBST (PBS + 0.05%
Tween-20) and incubated with horseradish peroxidase conjugated
Goat-anti-human IgG (Southern Biotech #2040-03) or Goat-anti-
human IgA (Southern Biotech #2050-05) in ELISA buffer for thirty
minutes. After a second wash step, plates were developed using a
TMB 2-Component Microwell Peroxidase Substrate Kit (SeraCare
#5120-0047) and background corrected absorbance (A450) was
determined using a Biotech Epoch plate reader with Gen5 soft-
ware. In the case of dIgA and SIgA, ELISA was carried out essentially
as described above with the exception of using a monoclonal
mouse anti-human J-chain antibody followed by HRP-conjugated
Goat-anti-mouse IgG (Southern Biotech #1030-05) for detection.
2.4. Hemagglutination inhibition assay
To measure the functional activity of anti-CfaE mAb3 and
mAb4, hemagglutination inhibition (HAI) assays were carried out
as described previously [28]. Briefly, ETEC cultures (strain
H10407) were diluted in PBS to an OD600 of 1.0. Human erythro-
cytes were washed in PBS and resuspended to a final concentration
of 1.5%. One hundred microliters of antibody in PBS was added to
the top wells of a 96-well U-bottom plates (Nunc Thermo Scien-
tific) in duplicate and titrated 2-fold down the plate in 50 lL PBS
followed by the addition of 50 lL ETEC and 50 lL D-mannose solu-
tion to each well. After a 10 min incubation, 50 lL of blood was
added to a final volume of 200 lL/well. Plates were statically incu-
bated for two hours at 4 C and hemagglutination observed with-
out magnification. Results are reported as the minimal inhibitory
concentration (IC100).
2.5. Statistical analysis
All data were analyzed using GraphPad Prism 8.0, with a p-
value of 0.05 being the cutoff for significance. Half maximal con-
centrations (½max) were determined by linear regression of log-
transformed ELISA data, and defined as the concentration of SIF-
incubated antibody resulting in 50% of the A450 of the averaged
undigested controls at 1 lg/mL. Samples with ½max > 1 lg/mL
were assigned a maximum in-assay value of 1.0 for purposes of
analysis. A significant difference in mean ½max over all timepoints
(including controls with no SIF) for each mAb was determined by
one-way ANOVA and without assuming unequal variances
between timepoints. The average time required to degrade 50%
of each mAb (T50%) was determined by interpolation from normal-
ized log-transformed data using a sigmoidal best fit model, and sig-
nificance determined by one-way ANOVA. Similar to the ½max
analysis, mAbs that failed to reach a T50% over the course of the
experiment were assigned a T50% equal to the longest timepoint
tested (120 min). Individual comparisons between two groups
were carried out using Welch’s T-test assuming unequal variances.
3. Results
3.1. Stability in SIF is influenced by mAb isotype, subclass, and
multimerization state
Along with IgM, IgG and SIgA (both A1 and A2) are the primary
mediators of adaptive immunity at mucosal sites. While all anti-
body therapeutics licensed to date have been of the IgG isotype,
sIgA-based enteric therapeutics offer the potential for higher avid-
ity, enhanced gastrointestinal stability and half-life, decreased sys-
temic exposure, and reduced inflammatory responses. Here we
assessed four mAbs targeting bacterial toxoid, fimbrial, and viral
antigens expressed as IgG and/or SIgA for gastrointestinal stability
using an in vitro SIF assay (Fig. S1). To better compare IgG with IgA,
monomeric and dimeric IgA were also evaluated for three of these
mAbs. The four mAbs displayed diverse variable gene usage, with
>90% identity to germline for VH domains and >94% identity for
VL, and CDRH3 lengths ranging from 11 to 19 amino acid residues
(Table S1).
Representative antigen-specific ELISA curves across timepoints
are shown in Fig. 1 (IgG and SIgA) and Fig. S2 (mIgA and dIgA).
Overall, loss of signal over the course of 120 min was observed
Fig. 1. Stability of antibodies in SIF is mediated by isotype and isomerization. IgG and monomeric, dimeric, and secretory IgA were incubated with SIF and tested for
antigen-specific binding over multiple timepoints by ELISA, with representative results for each antibody shown.
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for most isotypes and subclasses evaluated. The stability of each
mAb in SIF was impacted by the associated constant regions (IgG
vs. IgA), molecular structure (monomer vs. dimer), and the pres-
ence or absence of SC. The immunoreactivity of IgG1 decreased
over the course of the assay for mAbs1-3 (for mAb4, only SIgA
was tested) as determined by increasing ½max concentrations
over time, with all samples displaying ½max values outside of
the upper limit of the assay (1 lg/mL) by 120 min (Fig. 2). Signif-
icant loss of immunoreactivity was also observed for mIgA1 for
mAbs1-3, but was not observed for mIgA2 with the exception of
mAb3 (Fig. S3). In contrast to IgG, mean ½max values for mIgA
were <1 lg/mL over the course of the assay for both mAb1 and
mAb2 (Fig. S3). The time required for 50% (T50%) loss of signal
was also significantly shorter for IgG compared to mIgA1 for
mAb1 (31.8 compared to >120 min, p = 0.004) and mAb2 (16.8
compared to >120 min, p = 0.003) (Fig. 3). Finally, the percent
immunoreactivity remaining after 120 min in SIF was substantially
higher for mIgA1 and mIgA2 as compared to IgG for both mAb1
and mAb2 (Table 1). These data demonstrate the enhanced stabil-
ity of mIgA, particularly mIgA2, compared to IgG in our assay.
As the majority of mucosal IgA is in the form of dimer and
higher order multimers, we evaluated the effect of dimerization
on the stability of recombinant IgA. Significant loss of immunore-
activity over time was observed for dIgA1 as determined by ½max
concentrations (Fig. S3), and a trend towards loss of reactivity was
observed for mAb1 and mAb2 dIgA2. In the case of dIgA2, a small
sample size (N = 2) for mAb3 precluded a full analysis. Comparison
of monomers to dimers showed a significant difference in T50%
between mAb2 mIgA1 and dIgA1 (p = 0.002), but not between
other monomer and dimer pairs (Fig. 3). While such differences
may be present, they were not apparent over the two hour time
course that we examined. Overall, our results suggest that dimer-
Fig. 2. Antibodies expressed as SIgA demonstrate improved stability in SIF compared to IgG. SIF ½max concentrations mAbs1-3 IgG and mAbs1-4 SIgA are shown.
Samples with ½ Max concentrations >1 lg/mL (shown by a dotted line) were outside of the assay limits and are not displayed, however these samples were assigned a value
of 1 lg/mL for purposes of analysis.
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ization did not significantly improve stability in our assay, and
indeed suggest that dIgA may be less stable than monomeric forms
in some cases, though further investigations need to be carried out
to evaluate this.
The addition of SC can enhance proteolytic stability of dIgA as
well as increase retention time at mucosal surfaces by facilitating
association with the mucosal layer. Consistent with this protective
role for SC, a significant loss of immunoreactivity over time for
mAb1 and mAb2 was observed for only one SIgA (mAb2, SIgA1),
which nonetheless had a ½max of 0.22 lg/mL at the 120 min time
point (Fig. 2). Compared to IgG1, mAb1 and mAb2 SIgA1 and SIgA2
displayed lower ½max concentrations over the course of the assay,
significantly increased T50%s (p = 0.004 for mAb1 and p = 0.004 for
mAb2), and retained 4–5-fold greater immunoreactivity at the end
of the assay (Table 1, Figs. 2 and 3). Further, mAb1 and mAb2 SIgA
had low ½max concentrations over all time points, while those of
dIgA exceeded the upper limit of detection at later time points for
some replicates (Figs. 2 and S3). Although assay limitations pre-
vented significance comparisons of most mAb1 and mAb2 dIgA/
SIgA pairs (due to T50% values being >120 min), a significant differ-
ence was observed between mAb2 dIgA1 and SIgA1 T50%
(p = 0.002). No significant differences were observed between
secretory IgA1 and IgA2 for either mAb1 or mAb2. Taken together,
these data demonstrate significantly enhanced stability of SIgA
compared to IgG and mIgA/dIgA in SIF for some mAbs, and offer
support for the development and evaluation of SIgA-based enteric
therapeutics.
Unlike the patterns observed for mAb1 and mAb2, analysis of
mAb3 and mAb4 showed substantial losses of immunoreactivity
over time regardless of isotype and subclass tested (Table 1, Figs. 1–
Fig. 3. Antibody half-life is differentially impacted by isotype and multimerization state. Normalized T50% for each mAb was determined as the mean time in minutes for
a 50% reduction in immunoreactivity relative to a positive control. Antibodies that displayed >50% immunoreactivity over the course of the assay were assigned a T50% of
120 min for purposes of analysis and are shown on the graphs for clarity. Significance across mAbs for a given construct is shown at the top of each graph. Due to the small
sample size for mAb3 dIgA2 (N = 2), dIgA2 was not analyzed.
Table 1
Average (mean) normalized percent immunoreactivity remaining after 120 min
for all mAbs.
mAb1 mAb2 mAb3 mAb4
IgG 13.9 18.4 6.3
mIgA1 80.1 49.4 1.1
mIgA2 89.5 75.8 2.0
dIgA1 56.8 29.2 1.5
dIgA2 72.2 55.0 1.2
SIgA1 93.2 78.6 1.7 19.6
SIgA2 73.8 71.7 1.2 6.6
A.L. Wallace, M.I. Schneider, J.R. Toomey et al. Vaccine 38 (2020) 7490–7497
7494
3, S2-S3). No large isotype- or subclass- associated differences in
stability were observed for mAb3, with T50%s ranging from 3.6
to 9.9 min (Fig. 3) and most forms being completely degraded by
120 min regardless of isotype, molecular structure, or the presence
of SC (Table 1). Comparisons of mAb4 SIgA1 and SIgA2 showed that
SIgA1 had the better stability profile overall (mean T50% = 36.3 m
in), with 19.6% of signal remaining after 120 min (Table 1). Overall,
our results show that antibody isotype, multimerization state, and
the addition of secretory component can all impact the stability
profiles of mAbs.
It was notable that although the four mAbs used in this study
were cloned into the same vectors and had identical Fc regions
and structure, they nevertheless differed in their stability in SIF
as determined by ELISA. Significant differences in T50% values were
observed between the different mAbs expressed as IgG1 as well as
monomeric, dimeric, and secretory IgA. In the case of IgG1, all four
mAbs displayed rapid loss of immunoreactivity (Fig. 3), while for
other molecular forms mAb1 and mAb2 displayed better stability
profiles than did mAb3 and (for SIgA) mAb4. Interestingly, T50%
comparison between mAb1 and mAb2 showed that both were
quite stable (T50% >120 min) when expressed as mIgA1 but dis-
played different stability profiles when expressed as dIgA1,
(Figs. 2–3, S3 and Table 1). These data suggest the possibility that
the variable regions, as well as isotype and structure, may con-
tribute directly and/or indirectly to the stability profile of a given
mAb in some instances.
3.2. Antibody stability in SIF is associated with functional differences
The potential for high avidity and enhanced GI stability of sIgA
relative to IgG and mIgA has generated interest in its potential for
therapeutic use as a recombinant therapeutic. To investigate the
effects of incubation with SIF on the functional activity of SIgA,
we examined the ability of the anti-ETEC antibody mAb3
expressed as SIgA1 and SIgA2 to inhibit bacterial-mediated hemag-
glutination and compared it to SIgA from a second anti-ETEC mAb
(mAb4). The minimal inhibitory concentration (IC100) is reported as
the averaged results of two independent and blinded experiments
in Table 2. While SIF by itself had no detectable effect (top row),
the lower IC100 observed for mAb3 SIgA1 and SIgA2 and mAb4
SIgA1 at several time points compared to the positive control (no
SIF) may indicate that SIF did impact the assay to some extent,
though this does not affect comparisons between the different
SIF-treated mAbs. Of the four SIgAs tested, mAb4 SIgA2 was the
least functionally stable with IC100 above the detection limit of
the assay (>1.25 lg/mL) for all SIF-treated time points. MAb3 SIgA2
was more stable, with a detectable IC100 of 0.16 lg/mL at five min-
utes, followed by mAb3 SIgA1 which had a detectable IC100 up to
the 30 min time point. MAb4 SIgA1 proved to be the most stable,
with an IC100 of 1.25 lg/mL (the upper limit of detection for this
assay) even after two hours. These results were in agreement with
ELISA data, which showed similar patterns between these SIgAs,
and demonstrate that stability profiles in binding assays correlate
with functional differences. While SIgA1 was more functionally
stable than SIgA2 in this assay, further evaluations are clearly
needed prior to any conclusion regarding the overall functional
stability of mAb expressed as SIgA1 compared to SIgA2.
4. Discussion
Antibody Fc domains link effector functions to antigen binding
by variable regions, contribute to antibody polymerization (dIgA
and sIgA), and in the case of the Fc-associated secretory component
of sIgA, links adaptive and innate immune responses, facilitates the
association of the antibody with the intestinal mucosa, and can be
required for protection [30]. Resistance to GI-mediated cleavage
and retention of antibody binding capacity in the intestine are
therefore critical considerations for therapeutics development. To
date a number of simulated digestion models have been proposed,
and efforts have focused on incorporating all available information
across multiple studies regarding digestion parameters to develop
a next generation of standardized models [24,26,31]. One goal of
the current study was to use this information to allow for high-
throughput, small scale in vitro assessments of intestinal stability
profiles to facilitate early stage discovery of enteric therapeutics
prior to the use of more costly and time-consuming in vivo studies.
Given the functional benefits conferred by the association of vari-
able (VH/VL) and constant (Fc) regions, we focused on the stability
of intact mAb rather than the analysis of degradation products. Our
assay was designed to simulate the adult intestinal fasting state, as
it represents a harsher intestinal environment than that of the
adult or infant fed states [25,26,32], however it can be easily mod-
ified as needed to reflect a range of fed or fasting conditions and
could be added downstream to an in vitro simulated gastric fluid
(SGF) assay to generate a sequential SGF/SIF model. The current
SIF assay is especially advantageous for studies evaluating the sta-
bility, functionality, and retention time in the GI tract of oral
antibody-based therapeutics. As formulations for protection of
orally delivered antibody therapeutics from gastric digestion and
to facilitate release at luminal sites may range from encapsulation
strategies to the use of mAbs as a food additive or mixed into infant
formula [4,9,21], there will be an ongoing need to incorporate sta-
bility studies such as that proposed here to expedite discovery
pipelines and advance lead candidates to in vivo studies.
To date, all full length antibodies approved for clinical use by
the EMA and FDA have been IgG. IgG comprises approximately
70–85% of serum antibody, mediates a variety of effector functions,
and possesses a long serum half-life, making this an optimal iso-
type for many therapeutic mAbs [33,34]. IgA levels in serum are
low (15%, of which 90% is IgA1), but IgA is the dominant isotype
at mucosal surfaces in the lumen where it plays a critical role in
defense against pathogens and in mediating immune responses
to commensal bacteria, primarily in the form of sIgA [11,14]. In
the present study, IgG displayed the least favorable stability profile
compared to other monomers or dimeric forms. IgG is more sus-
ceptible to cleavage by trypsin, chymotrypsin, and duodenal fluid
than is IgA, though Fab cleaved from IgG can still bind antigen
[35], and the loss of immunoreactivity observed by ELISA was
likely due primarily to the cleavage of the Fc region, which would
impact detection. Nonetheless, Fab are susceptible to rapid clear-
ance from luminal surfaces due to peristalsis, which may limit
their window of efficacy as compared to intact mAb. Particularly
in the case of mAb1 and mAb2, IgA was more stable than IgG1,
while differences between all isotypes and subclasses tested were
Table 2
Effects of SIF incubation on antibody function evaluated by Hemagglutination
Inhibition Assay. The anti-ETEC mAbs 3 and 4 were incubated in SIF, and samples
frommultiple time points evaluated for their ability to inhibit hemagglutination. Each
assay was performed twice and the averaged result is reported as the minimal
concentration at which inhibition was observed (IC100 in lg/mL). The highest
concentration tested for inhibition was 1.25 lg/mL.
mAb3 mAb4
SIgA1 SIgA2 SIgA1 SIgA2
SIF control >1.25 >1.25 >1.25 >1.25
No SIF 0.64 0.94 0.94 0.94
T = 5 0.10 0.16 0.16 >1.25
T = 30 0.39 >1.25 0.31 >1.25
T = 60 >1.25 >1.25 0.63 >1.25
T = 120 >1.25 >1.25 1.25 >1.25
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less pronounced for mAb3 and mAb4. Our observations here are in
agreement with recently published stability tests in simulated gas-
tric fluid using mAb1, which also found enhanced stability of SIgA
compared to IgG1 for this antibody [22].
IgA1 is more susceptible to cleavage by a number of bacterially
secreted proteases than is IgA2, primarily due to the extended
hinge region of the former [11,12,36]. Consistent with these obser-
vations, we observed that mIgA2 was somewhat more stable than
mIgA1 in SIF (Fig. S3, Tables 1 and 2). Surprisingly, dimeric IgAs
were less stable than their corresponding monomers over the
120 min incubation in SIF as determined by ELISA. Although the
reason is unclear, we note that dIgA was detected using an anti-
J-chain mAb, whereas mIgA was detected using commercial HRP-
conjugated polyclonal IgA. Thus, cleavage of the a-tailpiece or else-
where in the constant region could completely abrogate detection
of dIgA, while mIgA might be less affected by such cleavages when
analyzed by ELISA. Further studies will need to be carried out to
fully characterize the relative intestinal stability of these two IgA
subclasses.
Secretory IgA (either dimeric or higher-order multimers) is the
dominant form of IgA in the mucosa, and has been shown to be
more stable than monomer and dimer not associated with SC
[12,36]. Consistent with this observation, our data showed that
SIgA1 and SIgA2 from mAb1 and mAb2 were quite stable over
the course of the experiment, with between 71% and 93% of total
mAb remaining intact after two hours (Table 1). We did not
observe any major differences between SIgA1 and SIgA2 for
mAb1 and mAb2; however, for mAb3 and mAb4 there did appear
to be a trend towards greater stability of SIgA1 as compared to
SIgA2, particularly in the case of mAb4 (Fig. 3, Table2). As the
two IgA subclasses are structurally distinct (with greater structural
heterogeneity being found in sIgA2) [12,18,37], selection of one
over the other may require empirical evaluation for any given
application. It was notable that the protective effect of SC was
much less pronounced for mAb2 and mAb4 compared to mAb1
and mAb2. Human SC contains five immunoglobulin-like domains
(D1-D5), and evidence indicates that D1 is critical for the initial
non-covalent association of SC with the Fc domains followed by
disulfide bond formation between D5 and IgA Ca2 domain
[38,39]. Previous studies have identified heterogeneous popula-
tions of dimer of which a fraction is conformationally unable to
associate properly with SC, leading to non-covalent binding
[40,41], and another study demonstrated that SC enhances stability
by delaying protease cleavage within the hinge region of IgA1 and
IgA2 [42]. While all mAbs tested in this assay were expressed in
CHO cells, other production methods, including transgenic plants
and yeast, are also being developed for production of SIgA
[20,21,23,43], and it is likely that structural differences due to sub-
class and allotype (IgA1, IgA2m1 and IgAm2) as well as the expres-
sion system and other factors may all contribute to the
gastrointestinal stability of a given mAb.
Despite being cloned into the same expression vectors, the
intestinal stability profiles of the four mAbs displayed considerable
variation. The differences in stability observed did not appear to
correlate with expression method (transient vs. stable), as stably
expressed mAb3 and mAb4 SIgA1 displayed no differences in sta-
bility when compared to the transiently-expressed mAbs used in
this study (data not shown). Similarly, column purification meth-
ods (CaptureSelect vs. Capto L) also did not correlate with the
observed patterns. Loss of immunoreactivity in our assay could
arise either from denaturation of the variable domain or compli-
mentary determining regions (CDRs) or alternatively as a conse-
quence of differing susceptibility to proteolytic cleavage and
degradation. While the first mechanism likely explains some of
the differences we observed, our results are consistent with previ-
ous studies showing that resistance to proteolytic cleavage is a pri-
mary determinant of antibody stability [35 11,12,36], and suggests
a possible role for variable domains in mediating stability through
limiting the exposure of cleavage sites or other mechanisms. While
this study did not investigate the underlying mechanisms respon-
sible for the differences we observed between antibodies, the
impact of the variable regions on stability and other molecular
properties has been described in other contexts [44,45]. A recent
report found that the degree of affinity maturation of human anti-
bodies is inversely related to thermal stability [46], and the influ-
ence of CDRs on the stability of humanized Fab displaying mouse
complementarity determining regions has been also been exam-
ined [47]. Given the limited number of mAbs tested in this study
we did not observe any correlation between stability and variable
region features such as CDR length, divergence from germline, or
gene family (Table S1), and factor(s) that may determine the
impact of the variable region on proteolytic stability in the GI envi-
ronment will require further evaluation.
Recombinant SIgA has been shown to display enhanced breadth
against influenza virus and to protect against Salmonellosis via pas-
sive immunization in mouse models, and SIgA-based camelid anti-
body fusions can protect piglets against ETEC when delivered
orally in feed [17,18,20,21]. In our functional study of anti-ETEC
mAbs, SIgA1 was more potent both in terms of IC100 and functional
stability over time compared to SIgA2, particularly for mAb4, and it
is possible that the presence of SC combined with the greater reach
and flexibility provided by the hinge of IgA1 compared to IgA2 may
explain the observed trends. As Fab fragments would also be
expected to be present in these samples, our data also suggests
that Fabs generated by cleavage may not be as effective as the
intact antibody in binding and agglutinating bacteria, at least in
this assay. In addition, and unlike full length SC associated IgA,
cleaved Fabs would not be tethered to the mucous and would be
more susceptible to clearance from the intestinal surface. Lastly,
it is also important to note that, although mAb3 and mAb4 had
poor stability profiles overall compared to mAb1 and mAb2, they
did inhibit agglutination, and in the case of mAb4 SIgA1 this was
true even after two hours. Thus, while any particular assay may
offer insights useful for the selection of lead mAbs, final selection
will need to be based upon an optimized balance of physical and
immunological qualities.
In conclusion, we have used an in vitro assay to evaluate the
proteolytic and functional stability of antibodies in the intestinal
environment. Our results show that intestinal stability is influ-
enced by isotype, subclass, variable region, and molecular struc-
ture, and highlight the utility of early stage in vitro assays such
as the one currently described. The use of IgA-based approaches
is supported by the enhanced gastrointestinal stability of the IgA
isotype as compared to IgG across the mAbs tested here. Finally,
these data provide additional evidence in support of the ongoing
development of SIgA-based therapeutic approaches targeting
enteric pathogens and disease.
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